Bruce Levy

Scientific Advisor at Thetis Pharma

Dr. Bruce Levy is a leading expert on Resolvin pharmacology in pulmonary diseases, and his seminal research on Resolvin E1 in ARDS and asthma models laid the foundation for Thetis’ TP-317 program. Dr. Levy is the Division Chief of the Pulmonary and Critical Care Medicine Division at Brigham and Women’s Hospital (BWH) and on the faculty at Harvard Medical School. The Bruce Levy Air Inflammation and Resolution Lab focuses on endogenous mechanisms for the resolution of lung inflammation and injury. The lab seeks to identify novel pathways and cellular targets that promote the resolution of pulmonary inflammation or injury and to determine roles for naturally-derived, specialized pro-resolving mediators in lung health and disease. Dr. Levy is board-certified in critical care medicine and pulmonary disease. He has written more than 120 peer-reviewed publications and currently serves as associate editor of the American Journal of Respiratory and Critical Care Medicine and The New England Journal of Medicine’s clinical problem-solving interactive case series. Dr. Levy received his medical degree from the University of Pennsylvania School of Medicine (now the Perelman School of Medicine) and completed a fellowship in pulmonary and critical care medicine at BWH.

Timeline

  • Scientific Advisor

    Current role